Drug intelligence / Profile preview

recombinant fimbrial adhesin dscCfaE

Development stage
Phase 2
Lead developer
U.S. Army Medical Research and Development Command
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Transcutaneous, Oral
01

Overview

Recombinant fimbrial adhesin dscCfaE is a donor strand-complemented form of the CfaE protein, which is the minor adhesive subunit located at the tip of CFA/I fimbriae from enterotoxigenic Escherichia coli (ETEC). This recombinant protein is engineered for increased stability and immunogenicity by fusing the C-terminal region of CfaB (the major pilin subunit) to the N-terminus of CfaE via a linker. The resulting molecule mimics the native conformation found on bacterial surfaces and serves as an antigen in vaccine formulations designed to prevent ETEC-induced diarrhea. The mechanism of action involves stimulating an immune response that generates neutralizing antibodies targeting ETEC adhesion to intestinal epithelial cells, thereby preventing colonization and subsequent diarrheal disease[2][3][5]. Clinical studies have shown that vaccines containing this antigen are safe and immunogenic in humans[3][4].

Other names
recombinant E. coli protein dscCfaEdonor strand-complemented CfaEETEC fimbrial tip adhesin vaccine
02

Targets

Sialic acid-containing glycoconjugateCfaE (Colonization factor antigen I minor subunit CfaE)

Beyond the preview

Go deeper on recombinant fimbrial adhesin dscCfaE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant fimbrial adhesin dscCfaE.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call